Cargando…

Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers

OBJECTIVES: To determine SARS-CoV-2-antibody prevalence in pediatric healthcare workers (pHCWs). DESIGN: Baseline prevalence of anti-SARS-CoV-2-IgG was assessed in a prospective cohort study from a large pediatric healthcare facility. Prior SARS-CoV-2 testing history, potential risk factors and anxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Claudia R., Sullivan, Patrick, Mantus, Grace, Sanchez, Travis, Zlotorzynska, Maria, Hanberry, Bradley, Iyer, Srikant, Heilman, Stacy, Camacho-Gonzalez, Andres, Figueroa, Janet, Manoranjithan, Shaminy, Leake, Deborah, Mendis, Reshika, Cleeton, Rebecca, Chen, Christie, Krieger, Rachel, Bush, Patricia, Hughes, Tiffany, Little, Wendalyn K., Suthar, Mehul S., Wrammert, Jens, Vos, Miriam B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952267/
https://www.ncbi.nlm.nih.gov/pubmed/33722686
http://dx.doi.org/10.1016/j.ijid.2021.03.017
Descripción
Sumario:OBJECTIVES: To determine SARS-CoV-2-antibody prevalence in pediatric healthcare workers (pHCWs). DESIGN: Baseline prevalence of anti-SARS-CoV-2-IgG was assessed in a prospective cohort study from a large pediatric healthcare facility. Prior SARS-CoV-2 testing history, potential risk factors and anxiety level about COVID-19 were determined. Prevalence difference between emergency department (ED)-based and non-ED-pHCWs was modeled controlling for those covariates. Chi-square test-for-trend was used to examine prevalence by month of enrollment. RESULTS: Most of 642 pHCWs enrolled were 31-40years, female and had no comorbidities. Half had children in their home, 49% had traveled, 42% reported an illness since January, 31% had a known COVID-19 exposure, and 8% had SARS-CoV-2 PCR testing. High COVID-19 pandemic anxiety was reported by 71%. Anti-SARS-CoV-2-IgG prevalence was 4.1%; 8.4% among ED versus 2.0% among non-ED pHCWs (p < 0.001). ED-work location and known COVID-19 exposure were independent risk factors. 31% of antibody-positive pHCWs reported no symptoms. Prevalence significantly (p < 0.001) increased from 3.0% in April–June to 12.7% in July–August. CONCLUSIONS: Anti-SARS-CoV-2-IgG prevalence was low in pHCWs but increased rapidly over time. Both working in the ED and exposure to a COVID-19-positive contact were associated with antibody-seropositivity. Ongoing universal PPE utilization is essential. These data may guide vaccination policies to protect front-line workers.